+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Multiple Sclerosis Market: Patient Numbers & Forecast (By Mode of Administration: Injectables Market, Infusions Market, Orals Market) - Actual & Unmet (Potential)

  • ID: 4396783
  • Report
  • Region: Global
  • 108 Pages
  • Renub Research
1 of 3
Global Multiple Sclerosis Market is Steadily Growing and it is Expected to Cross Over US$ 20 Billion Landmark by 2022

Global multiple sclerosis market is steadily growing and it is expected to cross over US$ 20 Billion landmark by 2022. Multiple sclerosis market is one of the most common neurological disorder diseases in the world. It is estimated that global multiple sclerosis patient numbers will increase around 35 Thousand by 2022. According to analysis, we have found that there is huge gap between actual and unmet market as disease modifying therapy receiving prevalence vary from country to country. Global multiple sclerosis unmet market is much higher compared to its actual market.

Reimbursement is key growth driver for Multiple Sclerosis market globally

Reimbursement is playing major role for the growth of multiple sclerosis market as multiple sclerosis drugs are too expensive and without reimbursement, it is nearly impossible to afford the treatment of MS by most of the multiple sclerosis patient in the world. Most of the European and North American countries have multiple sclerosis reimbursement policy; however eligibility criteria vary from country to country.

Multiple Sclerosis Drugs price is too expensive

Multiple sclerosis drugs price is steadily increasing which create a major challenge for the growth of multiple sclerosis market in the world. It is estimated that newly launched multiple sclerosis drugs are expensive than previous generation disease modifying drugs. According to our research, we have found that, United States multiple sclerosis drugs are nearly five times higher than European multiple sclerosis drugs price.

Injectables Disease Modifying Therapy Multiple Sclerosis Market is losing Ground

Injectables disease modifying therapy multiple sclerosis market is continuously declining. Newly launched orals disease modifying therapy is a growing market.

Global Multiple Sclerosis Market, Patient Numbers & Forecast (By Mode of Administration: Injectables Market, Infusions Market, Orals Market) - Actual & Unmet (Potential) has 108 pages with 93 figures and 1 Table, and provides 6 Countries: actual and potential/unmet patient numbers and market. This report also explains multiple sclerosis disease modifying therapy (DMT) mode of administration:

  • Actual Market is the current market which is already present
  • Unmet Market is the market which can be accomplished; but it has yet not been accomplished due to demand and supply gap. At present DMT receiving patients are less than total number of multiple sclerosis patient numbers.

6 Countries Multiple Sclerosis Market & Patients Treated Studied in the Report is as Follows:

1. United States
2. United Kingdom
3. Germany
4. France
5. Italy
6. Spain

Worldwide and United States Multiple Sclerosis Market & Patients Treated by Mode of administration:

1. Injectables
2. Infusions
3. Orals

Key Questions Answered in the Report?

  • What is multiple sclerosis market globally and its growth potential in Future?
  • How many number of patients treated by disease modifying therapy globally?
  • What is the multiple sclerosis market in United States and other European countries?
  • How many number of multiple sclerosis patients living in United States and other European countries?

Note: This report offers 10% free customization

Note: Product cover images may vary from those shown
2 of 3

1. Research Findings

2. Global Multiple Sclerosis Patient Numbers (2011 - 2022)
2.1 Patient Number & Forecast
2.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
2.3 By Mode of Administration - Injectables, Infusion, Oral Patient Numbers & Forecast
2.3.1 Injectables
2.3.2 Infusions
2.3.3 Orals

3. Global Multiple Sclerosis Market (2011 - 2022)
3.1 Unmet Market & Forecast
3.2 Market & Forecast
3.3 By Mode of Administration - Injectables, Infusions, Orals Market & Forecast
3.3.1 Injectables Market
3.3.2 Infusions Market
3.3.3 Orals Market

4. Patient Share - Global Multiple Sclerosis (2011 - 2022)
4.1 Patient Numbers Share & Forecast - (UK, France, Germany, Italy, Spain & United States)
4.2 Disease-Modifying Therapy (DMT) - (UK, France, Germany, Italy, Spain & United States)
4.3 By Mode of Administration - Injectables, Infusion, Oral

5. Market Share - Global Multiple Sclerosis (2011 - 2022)
5.1 Unmet Market Share & Forecast - (UK, France, Germany, Italy, Spain & United States)
5.2 Market Share & Forecast - (UK, France, Germany, Italy, Spain & United States)
5.3 By Mode of Administration - Injectables, Infusion, Oral

6. United Kingdom
6.1 Multiple Sclerosis Patient Numbers (2011 - 2022)
6.1.1 Patient Number & Forecast
6.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
6.2 Multiple Sclerosis Market (2011 - 2022)
6.2.1 Unmet Market & Forecast
6.2.2 Market & Forecast

7. France
7.1 Multiple Sclerosis Patient Number (2011 - 2022)
7.1.1 Patient Number & Forecast
7.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
7.2 Multiple Sclerosis Market (2011 - 2022)
7.2.1 Unmet Market & Forecast
7.2.2 Market & Forecast

8. Germany
8.1 Multiple Sclerosis Patient Number (2011 - 2022)
8.1.1 Patient Number & Forecast
8.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
8.2 Multiple Sclerosis Market (2011 - 2022)
8.2.1 Unmet Market & Forecast
8.2.2 Market & Forecast

9. Italy
9.1 Multiple Sclerosis Patient Number (2011 - 2022)
9.1.1 Patient Number & Forecast
9.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
9.2 Multiple Sclerosis Market (2011 - 2022)
9.2.1 Unmet Market & Forecast
9.2.2 Market & Forecast

10. Spain
10.1 Multiple Sclerosis Patient Number (2011 - 2022)
10.1.1 Patient Number & Forecast
10.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
10.2 Multiple Sclerosis Market (2011 - 2022)
10.2.1 Unmet Market & Forecast
10.2.2 Market & Forecast

11. United States
11.1 Multiple Sclerosis Patient Numbers (2011 - 2022)
11.1.1 Patient Number & Forecast
11.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
11.2 By Mode of Administration
11.2.1 Injectables Patients Numbers
11.2.2 Infusions Patients Numbers
11.2.3 Orals Patient Numbers
11.3 United States Multiple Sclerosis Market (2011 - 2022)
11.3.1 Unmet Market & Forecast
11.3.2 Market & Forecast
11.4 By Mode of Administration
11.4.1 Injectables Market
11.4.2 Infusions Market
11.4.3 Orals Market

12. Growth Drivers (Due to data confidentiality, growth factors have not been disclosed in this table of contents)
12.1 Point no. 1
12.2 Point no. 2

13. Challenges (Due to data confidentiality, challenges have not been disclosed in this table of contents)
13.1 Point no. 1
13.2 Point no. 2
13.3 Point no. 3

14. Appendix

List of Figures
Figure 2-1: Global - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
Figure 2-2: Global - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
Figure 2-3: Global - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
Figure 2-4: Global - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
Figure 2-5: Global - Multiple Sclerosis Injectables Patient Numbers (Thousand), 2011 - 2016
Figure 2-6: Global - Forecast for Multiple Sclerosis Injectables Patient Numbers (Thousand), 2017 - 2022
Figure 2-7: Global - Multiple Sclerosis Infusions Patient Numbers (Thousand), 2011 - 2016
Figure 2-8: Global - Forecast for Multiple Sclerosis Infusions Patient Numbers (Thousand), 2017 - 2022
Figure 2-9: Global - Multiple Sclerosis Orals Patient Numbers (Thousand), 2011 - 2016
Figure 2-10: Global - Forecast for Multiple Sclerosis Orals Patient Numbers (Thousand), 2017 - 2022
Figure 3-1: Global - Multiple Sclerosis Unmet Market (Billion US$), 2011 - 2016
Figure 3-2: Global - Forecast for Multiple Sclerosis Unmet Market (Billion US$), 2017 - 2022
Figure 3-3: Global - Multiple Sclerosis Market (Billion US$), 2011 - 2016
Figure 3-4: Global - Forecast for Multiple Sclerosis Market (Billion US$), 2017 - 2022
Figure 3-5: Global - Multiple Sclerosis Injectables Market (Million US$), 2011 - 2016
Figure 3-6: Global - Forecast for Multiple Sclerosis Injectables Market (Million US$), 2017 - 2022
Figure 3-7: Global - Multiple Sclerosis Infusions Market (Million US$), 2011 - 2016
Figure 3-8: Global - Forecast for Multiple Sclerosis Infusions Market (Million US$), 2017 - 2022
Figure 3-9: Global - Multiple Sclerosis Orals Market (Million US$), 2011 - 2016
Figure 3-10: Global - Forecast for Multiple Sclerosis Orals Market (Million US$), 2017 - 2022
Figure 4-1: Global - Patient Numbers Share (Percent), 2011 - 2016
Figure 4-2: Global - Forecast for Patient Numbers Share (Percent), 2017 - 2022
Figure 4-3: Global - Disease-Modifying Therapy (DMT) Patient Numbers Share (Percent), 2011 - 2016
Figure 4-4: Global - Forecast for Disease-Modifying Therapy (DMT) Patient Numbers Share (Percent), 2017 - 2022
Figure 4-5: Global - Multiple Sclerosis Mode of Administration Patient Numbers Share (Percent), 2011 - 2016
Figure 4-6: Global - Forecast for Multiple Sclerosis Mode of Administration Patient Numbers Share (Percent), 2017 - 2022
Figure 4-7: Global - Multiple Sclerosis Unmet Market Share (Percent), 2011 - 2016
Figure 4-8: Global - Forecast for Multiple Sclerosis Unmet Market Share (Percent), 2017 - 2022
Figure 4-9: Global - Multiple Sclerosis Market Share (Percent), 2011 - 2016
Figure 4-10: Global - Forecast for Multiple Sclerosis Market Share (Percent), 2017 - 2022
Figure 4-11: Global - Multiple Sclerosis Market by Mode of Administration Share (Percent), 2011 - 2016
Figure 4-12: Global - Forecast for Multiple Sclerosis Market by Mode of Administration Share (Percent), 2017 - 2022
Figure 5-1: United Kingdom - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
Figure 5-2: United Kingdom - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
Figure 5-3: United Kingdom - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
Figure 5-4: United Kingdom - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
Figure 5-5: United Kingdom - Multiple Sclerosis Unmet Market (Million US$), 2011 - 2016
Figure 5-6: United Kingdom - Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 - 2022
Figure 5-7: United Kingdom - Multiple Sclerosis Market (Million US$), 2011 - 2016
Figure 5-8: United Kingdom - Forecast for Multiple Sclerosis Market (Million US$), 2017 - 2022
Figure 6-1: France - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
Figure 6-2: France - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
Figure 6-3: France - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
Figure 6-4: France - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
Figure 6-5: France - Multiple Sclerosis Unmet Market (Million US$), 2011 - 2016
Figure 6-6: France - Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 - 2022
Figure 6-7: France - Multiple Sclerosis Market (Million US$), 2011 - 2016
Figure 6-8: France - Forecast for Multiple Sclerosis Market (Million US$), 2017 - 2022
Figure 7-1: Germany - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
Figure 7-2: Germany - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
Figure 7-3: Germany - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
Figure 7-4: Germany - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
Figure 7-5: Germany - Multiple Sclerosis Unmet Market (Million US$), 2011 - 2016
Figure 7-6: Germany - Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 - 2022
Figure 7-7: Germany - Multiple Sclerosis Market (Million US$), 2011 - 2016
Figure 7-8: Germany - Forecast for Multiple Sclerosis Market (Million US$), 2017 - 2022
Figure 8-1: Italy - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
Figure 8-2: Italy - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
Figure 8-3: Italy - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
Figure 8-4: Italy - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
Figure 8-5: Italy - Multiple Sclerosis Unmet Market (Million US$), 2011 - 2016
Figure 8-6: Italy - Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 - 2022
Figure 8-7: Italy - Multiple Sclerosis Market (Million US$), 2011 - 2016
Figure 8-8: Italy - Forecast for Multiple Sclerosis Market (Million US$), 2017 - 2022
Figure 9-1: Spain - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
Figure 9-2: Spain - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
Figure 9-3: Spain - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
Figure 9-4: Spain - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
Figure 9-5: Spain - Multiple Sclerosis Unmet Market (Million US$), 2011 - 2016
Figure 9-6: Spain - Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 - 2022
Figure 9-7: Spain - Multiple Sclerosis Market (Million US$), 2011 - 2016
Figure 9-8: Spain - Forecast for Multiple Sclerosis Market (Million US$), 2017 - 2022
Figure 10-1: United States - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
Figure 10-2: United States - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
Figure 10-3: United States - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
Figure 10-4: United States - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
Figure 10-5: United States - Multiple Sclerosis Injectables Patient Numbers (Thousand), 2011 - 2016
Figure 10-6: United States - Forecast for Multiple Sclerosis Injectables Patient Numbers (Thousand), 2017 - 2022
Figure 10-7: United States - Multiple Sclerosis Infusions Patient Numbers (Thousand), 2011 - 2016
Figure 10-8: United States - Forecast for Multiple Sclerosis Infusions Patient Numbers (Thousand), 2017 - 2022
Figure 10-9: United States - Multiple Sclerosis Orals Patient Numbers (Thousand), 2011 - 2016
Figure 10-10: United States - Forecast for Multiple Sclerosis Orals Patient Numbers (Thousand), 2017 - 2022
Figure 10-11: United States - Multiple Sclerosis Unmet Market (Billion US$), 2011 - 2016
Figure 10-12: United States - Forecast for Multiple Sclerosis Unmet Market (Billion US$), 2017 - 2022
Figure 10-13: United States - Multiple Sclerosis Market (Billion US$), 2011 - 2016
Figure 10-14: United States - Forecast for Multiple Sclerosis Market (Billion US$), 2017 - 2022
Figure 10-15: United States - Multiple Sclerosis Injectables Market (Million US$), 2011 - 2016
Figure 10-16: United States - Forecast for Multiple Sclerosis Injectables Market (Million US$), 2017 - 2022
Figure 10-17: United States - Multiple Sclerosis Infusions Market (Million US$), 2011 - 2016
Figure 10-18: United States - Forecast for Multiple Sclerosis Infusions Market (Million US$), 2017 - 2022
Figure 10-19: United States - Multiple Sclerosis Orals Market (Million US$), 2011 - 2016
Figure 10-20: United States - Forecast for Multiple Sclerosis Orals Market (Million US$), 2017 - 2022
Figure 12-1: Europe - Number of Neurologists per 100,000 Specialized in MS vs. Percent of MS Population Receiving DMDs, 2013

List of Tables
Table 11 1: Europe - Reimbursements for Disease Modifying Drugs (DMDs), 2013

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll